Enthera Pharmaceuticals

About Enthera Pharmaceuticals

Enthera Pharmaceuticals is a clinical-stage biotechnology company headquartered in Milan, Italy, established in 2016 by Professor Paolo Fiorina and Dr. Francesca D'Addio. The company was the first spin-off from BiovelocITA, Italy's pioneering biotech accelerator. Fiorina, an endocrinologist with extensive research experience in autoimmune diabetes and islet transplantation, and D'Addio, who serves as Head of Preclinical Research, leveraged their scientific work to found the company. Their research backgrounds in immunology and diabetes at institutions like the University of Milan and Boston Children's Hospital are foundational to the company's approach.

The company's business is centered on developing first-in-class biologics to address underserved autoimmune conditions, primarily focusing on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). Enthera's strategy is not to merely manage symptoms but to develop disease-modifying treatments that preserve and restore organ function. The company operates in the biopharmaceutical market, and its business model involves significant research and development, funded by venture capital, with the goal of bringing novel drugs through clinical trials to market. Enthera has successfully raised a total of €35 million in its Series A financing, which was noted as the largest for an Italian biotech company at the time. This funding was secured from a syndicate of international investors, including Sofinnova Partners, AbbVie Ventures, Roche Venture Fund, and the JDRF T1D Fund.

Enthera's core therapeutic concept is based on the discovery of the IGFBP3/TMEM219 pathway, which plays a role in the programmed cell death (apoptosis) of stem cells in the gut and insulin-producing beta cells in the pancreas. The company's proprietary discovery platform generates a library of monoclonal antibodies (mAbs) and fusion proteins designed to inhibit this pathway. Its lead product candidate is Ebrasodebart (Ent001), a monoclonal antibody that targets the TMEM219 receptor. By binding to this receptor, Ent001 is designed to prevent the cell death that underlies both IBD and T1D. This approach is distinct because it aims to restore the body's own cell compartments—the intestinal structure in IBD and the pancreatic beta cells in T1D. In March 2023, Enthera initiated a Phase 1 clinical trial for Ent001 in healthy volunteers, marking its transition to a clinical-stage company. The company has since completed the single ascending dose portion of the trial and has initiated a Phase 1b trial in patients with ulcerative colitis.